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Background: Knowledge of the rate of action of compounds against cultured malaria parasites is required to
determine the optimal time-points for drug mode of action studies, as well as to predict likely in vivo parasite
clearance rates in order to select optimal hit compounds for further development. In this study, changes in parasite
ATP levels and transgenic luciferase reporter activity were explored as means to detect drug-induced stress in
cultured parasites.
Methods: In vitro cultures of Plasmodium falciparum 3D7 wild-type or firefly luciferase-expressing parasites were
incubated with a panel of six anti-malarial compounds for 10 hours and parasite ATP levels or luciferase activity
determined at two-hour intervals using luminescence-based reagents. For comparative purposes, parasite
morphology changes were evaluated by light microscopy, as well as the extent to which parasites recover after 48
hours from a six-hour drug treatment using a parasite lactate dehydrogenase assay.
Results: Changes in parasite ATP levels displayed three phenotypes: mild or no change (chloroquine, DFMO); 2–4
fold increase (mefloquine, artemisinin); severe depletion (ritonavir, gramicidin). The respective phenotypes and the
rate at which they manifested correlated closely with the extent to which parasites recovered from a six-hour drug
treatment (with the exception of chloroquine) and the appearance and severity of morphological changes
observed by light microscopy. Luciferase activity decreased profoundly in parasites treated with mefloquine,
artemisinin and ritonavir (34-67% decrease in 2 hours), while chloroquine and DFMO produced only mild changes
over 10 hours. Gramicidin yielded intermediate decreases in luciferase activity.
Conclusions: ATP levels and luciferase activity respond rapidly to incubation with anti-malarial drugs and provide
quantitative read-outs to detect the appearance and magnitude of drug-induced stress in cultured parasites. The
correlation between the observed changes and irreversible parasite toxicity is not yet sufficiently clear to predict
clinical clearance rates, but may be useful for ranking compounds against each other and standard drugs vis-à-vis
rate of action and for determining early time-points for drug mode of action studies.
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DFMOBackground
The ability of the malaria parasite Plasmodium falcip-
arum to develop resistance to drugs motivates the crit-
ical need to deliver new development candidates to
bolster the current clinical pipeline [1]. Large-scale
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reproduction in any medium, provided the orespecially successful in identifying numerous early hit
compounds against cultured parasites [2]. Compared to
these phenotypic screening programmes, target-based
discovery approaches have been less successful, perhaps
partially due to the lack of extensively validated drug tar-
gets. Further characterization of priority hit compounds
may include an investigation of their modes of action,
which could also yield new potential targets for malaria
drug discovery. The mode of action of a compound may
be assessed by determining the effect of the compoundd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a more global approach, e.g. transcriptomic, proteomic
and/or metabolomic profiling [3]. These studies require
knowledge of the rate of action of a compound and
should ideally be performed at early time-points when
the compound starts exerting its primary effect(s), as
opposed to later time-points when the primary mode of
action may conceivably be obscured by non-specific sec-
ondary responses in the parasite. Moreover, a highly de-
sirable property of anti-malarial compounds is that they
should kill parasites rapidly, in order to reduce the
required dosages in clinical use, minimize the likelihood
of resistance development, and increase patient compli-
ance. This requires an accurate determination of the rate
of action of promising compounds against malaria para-
sites, particularly to enable researchers to rank com-
pounds for further pre-clinical and clinical development.
A parasite reduction ratio (PRR) assay was recently
described to predict the rate of parasite clearance in vivo
by measuring the extent to which parasites recover from
drug exposure for defined periods of time in in vitro cul-
tures [4]. However, for mode of action studies, the rate
of action is conventionally assessed by evaluating para-
site morphological changes over time during drug ex-
posure using Giemsa-stained blood smears and light
microscopy. While this technique is relatively simple to
perform, it is time-consuming, highly susceptible to sub-
jective interpretation and difficult to express quantita-
tively, unless the morphological changes are drastic and
uniform. Making the distinction between parasites with
normal vs aberrant drug-induced morphologies is par-
ticularly challenging due to the heterogeneous morph-
ology of individual parasites under routine culture
conditions, the tendency of individual cells to display a
spectrum of mild to severe morphological abnormalities,
particularly at early time-points, and the challenge of
preparing uniform microscopy preparations on separate
occasions.
In this study, ATP quantitation and luciferase activity
measurements as a means to detect the rate and severity
of drug-induced stress in in vitro cultures of Plasmo-
dium falciparum was explored. ATP content in cells as
an indicator of metabolic status could conceivably be
used to detect abnormal metabolic activity imposed by
drug action, while luciferase activity in transgenic para-
sites was unexpectedly found to decrease rapidly and
profoundly during drug exposure, which may be
exploited as a novel indicator of the rate of drug-
induced stress. The rate, magnitude and nature of the
changes in parasite ATP content and luciferase activity
levels over 10-hour incubation periods were character-
ized using a panel of six compounds with different
modes of action: the clinical anti-malarial drugs chloro-
quine, mefloquine and artemisinin, and the experimentalcompounds DL-α-difluoromethyl ornithine (DFMO), an
inhibitor of polyamine biosynthesis [5], ritonavir, an HIV
aspartyl protease inhibitor with known anti-malarial ac-
tivity [6] and gramicidin, a mixture of channel forming
ionophores for monovalent cations [7].
Methods
Parasite cultivation, morphological evaluation and drug
IC50 determination
Plasmodium falciparum 3D7 cultures were maintained
at 37°C in medium consisting of RPMI 1640 supplemen-
ted with 2mM L-glutamine, 25mM Hepes, 20mM glu-
cose, 0.65 mM hypoxanthine, 60 μg/mL gentamycin,
2.5% (w/v) Albumax II and 3% (v/v) type O+ red blood
cells in flasks suffused with a mixture of 5% CO2, 5% O2,
90% N2. Parasite life-cycles were routinely synchronized
by the sorbitol method [8]. Parasite morphology was
assessed by light microscopy of methanol fixed and
Giemsa-stained thin blood smears using a 100x oil-
immersion objective. Images were captured with an
Olympus BX41 upright microscope equipped with a
CC12 Soft Imaging system. Drug 50% inhibitory concen-
trations (IC50) were determined by measuring parasite
viability after a 48h incubation with 3-fold serial dilu-
tions of the drugs using the parasite lactate dehydrogen-
ase (pLDH) assay [9]. IC50 values were derived from
non-linear regression dose–response plots prepared with
GraphPad Prism (v.5.02).
Drug compounds used in this study
Chloroquine diphosphate, mefloquine hydrochloride,
artemisinin and gramicidin from Bacillus brevis were
purchased from Sigma-Aldrich. DL-α-difluoromethylor-
nithine (DFMO) was kindly provided by P. Woster
(Wayne State University, MI) and ritonavir purchased
from Kinbester Co. (Xiamen, China). The compounds
were prepared as 10mM stock solutions in DMSO (ar-
temisinin, gramicidin, ritonavir), methanol (mefloquine)
or water (chloroquine, DFMO). The proteasome inhibi-
tors lactacystin and MG-132 were purchased from
Merck and prepared as 10mM stocks in water and
DMSO, respectively. Final concentrations of the drug
compounds used in all assays in this study were: 100
nM chloroquine; 100 nM mefloquine; 100 nM artemisi-
nin (ATP, morphology and recovery assays); 500 nM
artemisinin (luciferase assay); 0.1 nM gramicidin; 10
mM DFMO; 100 μM ritonavir; 5 μM lactacystin; 300
nM MG-132.
Parasite recovery assay
An early trophozoite-stage culture was used to prepare a
2% haematocrit, 2% parasitaemia suspension in culture
medium which was distributed into 6-well plates at 2.5
mL per well. The plates were treated with drug and
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itional plate was prepared with uninfected RBCs in trip-
licate wells to serve as a background control. The plates
were transferred to an airtight chamber suffused with
5% CO2, 5% O2, 90% N2 and incubated at 37°C for six
hours. Following incubation, the contents of each well
was mixed well and 800 μL was transferred to a sterile
microfuge tube to pellet the infected red blood cells.
The pellet was washed three times in 1 mL of culture
medium pre-warmed at 37°C and then resuspended in
fresh medium at a haematocrit of 1%. The suspension
was transferred to a 96-well plates at 200 μL per well.
Parasite lactate dehydrogenase activity [9] was measured
in the plate after it was returned to the airtight chamber,
gassed and incubated at 37°C for 48 hours. The pLDH
activity was used to calculate the percentage parasite via-
bility after 48h for each respective drug, relative to solv-
ent controls.
ATP assay
To quantitate changes in parasite ATP content during
drug exposure, early trophozoite-stage cultures were
used to prepare a 32 mL 5% haematocrit, 2% parasit-
aemia suspension in culture medium. The suspension
was split into 2 x 15 mL cultures and incubated in cul-
ture flasks at 37°C with drug compounds and solvent
control solutions, respectively. Three 500 μL aliquots of
the culture suspensions were removed from the control
and treated cultures, respectively, every 2 hours over a
10-hour period and transferred to cold microfuge tubes
placed on ice. The infected red blood cells in the 500 μL
samples were pelleted by centrifugation at 8,000 rpm for
30 seconds in a microfuge and lysed by adding 500 μL
0.24% (w/v) saponin, 0.1% (w/v) bovine serum albumin
(BSA) in phosphate-buffered saline (PBS). Complete
RBC lysis was achieved by vortexing the solution for ap-
proximately 45 seconds until translucent. The lysate was
removed and pipetted onto the surface of a 300 μL mix-
ture of dibutyl phthalate and dioctyl phthalate (5:4) in a
microfuge tube and centrifuged at 14,000 rpm for 40
seconds. This resulted in the intact parasites pelleting at
the bottom of the tube, while the aqueous RBC lysate
settled above the intervening phthalate oil layer. The
aqueous layer was aspirated off and the inner surface of
the tube above the oil layer and the top of the oil layer
carefully washed with 500 μL of 0.1% (w/v) BSA in PBS
to completely remove all traces of RBC lysate. The oil
layer was aspirated off, 150 μL ice-cold PBS added onto
the parasite pellet and the sample snap-frozen in liquid
nitrogen and stored at −20°C. ATP levels were subse-
quently measured by thawing the samples at room
temperature, resuspending the parasite pellets by pipet-
ting, transferring 50 μL to a white 96-well plate and add-
ing 50 μL of CellTitre-GloW reagent (Promega). Theplate was briefly agitated and then incubated in the dark
for 10 minutes at room temperature before measuring
luminescence in Tecan Infinite F500 plate reader. Aver-
age background luminescence readings from wells con-
taining PBS alone were subtracted from the sample
readings.
Preparation of luciferase transgenic parasites
To obtain an expression plasmid for stable episomal ex-
pression of luciferase, the expression and selection cas-
settes of pHTK were sub-cloned into the NotI and NcoI
sites of pGEM-T Easy (Promega). The pHTK expression
cassette consists of the P. falciparum heat-shock protein
hsp86 5’-untranslated promoter region, the Herpes sim-
plex virus thymidine kinase coding sequence flanked by
XhoI sites and the P. berghei 3’ termination region, while
the selection cassette contains the human dihydrofolate
reductase (hdhfr) coding sequence flanked by the P. fal-
ciparum calmodulin 5’-untranslated promoter region
and the P. falciparum histidine-rich protein 2 3’-
untranslated region in a head-to-head orientation with
the expression cassette [10]. The coding sequence of the
Photinus pyralis luciferase gene, flanked by NheI and
XhoI restriction sites, was PCR amplified from the pGL2
plasmid (Promega) and replaced the thymidine kinase
sequence in the pHTK expression cassette to obtain
pHsp-Luc. The plasmid was used to transfect P. falcip-
arum 3D7 parasites by electroporation (0.31 kV, 950μF)
in a BioRad Gene-Pulser electroporator and stable lines
selected by culturing in medium supplemented with 2.5
nM WR99210 according to previously described proto-
cols [11].
Luciferase assay
Transgenic luciferase-expressing parasite cultures at the
early trophozoite stage were used to prepare 5% haem-
atocrit, 2% parasitaemia suspensions in culture medium
and 200 μL transferred to wells in a 96-well culture
plate. A separate plate was prepared for each 2-hour
time-point of the assay. Test drug compounds and solv-
ent control solutions were added to triplicate wells in
the plate, while uninfected RBCs at 5% haematocrit (200
μL) were added to triplicate wells as background con-
trols. The plates were transferred to an airtight chamber
suffused with 5% CO2, 5% O2, balance N2 and incubated
at 37°C. At 2-hour intervals, one plate was carefully
removed from the chamber without disturbing the
settled RBCs and 150 μL of supernatant was removed
from all wells, followed by the addition of 100 μL per
well of GloW Lysis Buffer (Promega). After 5 minutes in-
cubation at room temperature, the contents of the wells
were mixed by pipetting, 100 μL transferred to a white
96-well plate 100 μL of Bright-GloW Luciferase Assay
System reagent (Promega) added and the luminescence
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multimode plate reader. The average luminescence read-
ings obtained from uninfected red blood cell wells were
subtracted as background from those obtained with
drug-treated and untreated infected red blood cell
cultures.
Results
Drug-induced changes in parasite ATP levels
An assay format based on the use of the luminescent
CellTitre-GloW reagent (Promega) was developed for de-
termining changes in parasite ATP levels. Briefly, ali-
quots were removed from test and control cultures and
transferred to microfuge tubes. To remove extraneous
RBC-associated ATP, the cells were lysed in saponin and
the parasites separated from the lysate by centrifugation
through a phthalate oil layer. The parasite pellets were
resuspended in CellTitre-GloW reagent, transferred to
microtitre plates and luminescence read in a multimode
plate reader. In trophozoite-stage cultures, the assay
routinely yielded luminescence signals more than 250-
fold higher than those obtained with uninfected RBC
controls, producing Z’-factor values [12] of 0.95-0.97,
and luminescence correlated linearly with parasite num-
bers over the range 1x105 – 2x106 (Additional file 1).
To determine if parasite ATP levels change in re-
sponse to drug-induced stress, and the dimensions and
rates of the changes, early trophozoite-stage cultures
were incubated with a panel of six anti-malarial drug
compounds and aliquots were removed at 2-hour inter-
vals over a 10-hour period to quantify ATP content rela-
tive to untreated controls (Figure 1). Compound
concentrations used were approximately 5 times their
IC50s determined using the parasite lactate dehydrogen-
ase assay and published data (Additional file 2). In para-
sites exposed to chloroquine and DFMO (Figures 1A
and 1B, respectively), ATP levels matched those of un-
treated control parasites over the entire 10-hour incuba-
tion period (t-test P values >0.05 at all time-points).
Note that the ATP levels in control parasites fluctuate
extensively during the trophozoite stage (Additional
file 3). By contrast, in mefloquine-treated parasites
(Figure 1C) there was a marked 2.4-fold increase in ATP
by the 4h time-point and ATP levels remained consist-
ently elevated above those of controls during the re-
mainder of the 10-hour incubation, although the 8h and
10h luminescence values display t-test P values >0.05
compared to the controls. A more profound and rapid
increase in ATP content was observed during artemisi-
nin treatment (Figure 1D). ATP content was 4.5-fold
higher than those of untreated parasites at the 2h time-
point and remained raised 1.8 to 2.4-fold during the rest
of the 10-hour incubation (P<0.05 at all time-points). In
marked contrast, ritonavir and gramicidin treatmentcaused a rapid and sharp decrease in parasite ATP levels
(Figures 1E and 1F). Parasite ATP content was essen-
tially depleted (luminescence <5% relative to controls) at
the 2h and 4h time-points after addition of ritonavir and
gramicidin, respectively.
To assess whether the observed responses of parasite
ATP levels to drug exposure corresponded with mor-
phological changes, Giemsa-stained smears were pre-
pared at all time-points during the incubations and
viewed by light microscopy (representative parasite
images at the 8h time-point for chloroquine and DFMO
and 6h time-point for the remaining drugs shown in
Figure 2). Treatment with chloroquine and DFMO did
not significantly alter parasite ATP levels and also
produced the mildest morphological changes during the
10-hour incubation. Treated and control parasite morph-
ologies were indistinguishable over most of the incuba-
tion period (Figure 2). A modest reduction in parasite
size could be discerned at the 8h and 10h time-points,
perhaps suggestive of slower parasite growth (i.e. cell
cycle delay). In the mefloquine-treated parasite popula-
tion, marked evidence of reduced parasite growth (i.e.
smaller size) was observed at the 6h time-point (Figure 2),
becoming more prominent later. Irregularly shaped and
pyknotic (highly shrunken and stained deep purple) para-
sites were also observed at later time-points, but these
represented a minority of the parasite population. Arte-
misinin treatment produced similar morphological
changes to those accompanying mefloquine treatment,
although irregularly shaped parasites were observed earl-
ier, at 6h (examples shown in Figure 2). Ritonavir and
gramicidin rapidly depleted parasite ATP levels and also
produced the most rapid and significant morphological
deterioration of the parasites. In ritonavir-treated cul-
tures, a reduction in parasite size, abnormal morpholo-
gies and pyknotic cells were prevalent at 4h, and the
latter predominated at later time-points (Figure 2). The
same morphological changes were observed with
gramicidin-treated parasites, with a preponderance of
pyknotic (presumably dead) parasites at 6h (Figure 2).
Conceivably, increased ATP levels observed with mef-
loquine and artemisinin may represent a parasite meta-
bolic response to cope with drug-induced stress, while
the marked reduction in ATP observed with ritonavir
and gramicidin indicates a serious deterioration in para-
site metabolism. The question arose to what extent these
changes reflect a terminal compromise in parasite viabil-
ity. To address this, a short “parasite recovery assay” was
performed. Briefly, parasite cultures were incubated with
the respective drug compounds for 6h, after which the
compounds were removed by washing and the treated
parasites returned to culture for an additional 48h. After
the 48h incubation, parasite levels were determined
by measuring parasite lactate dehydrogenase (pLDH)













































































































































Figure 1 Variation in ATP levels in drug-treated parasites. Plasmodium falciparum 3D7 parasite cultures were incubated for 10 hours with 100
nM chloroquine (A), 10 mM DFMO (B), 100 nM mefloquine (C), 100 nM artemisinin (D), 100 μM ritonavir (E) or 0.1 nM gramicidin (F). At 2-hour
intervals, aliquots were removed from drug exposed (solid line) and solvent control (dotted line) cultures, parasites were isolated by saponin lysis
and centrifugation through a phthalate oil layer, and their ATP content determined with a luminescence based CellTitre-GloW reagent (Promega).
Individual data-points are mean luminescence values (relative light units – RLU) from three aliquots per culture processed in parallel and error
bars indicate the standard deviation.
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untreated controls (Figure 3). Consistent with the mod-
est ATP and morphological changes observed previously
with DFMO treatment, parasites were able to recover ef-
fectively from the 6h exposure to DFMO and achieved
85% parasite viability. Mefloquine and artemisinin treat-
ment for 6h resulted in a more irreversible loss of para-
site viability and parasite levels of 56% and 46% relative
to controls were obtained for the two drugs, respectively.
By comparison, only 11% and 21% of ritonavir- and
gramicidin-treated parasites, respectively, recoveredfrom the 6-hour drug treatment, compared to untreated
controls. Unexpectedly, considering the mild ATP and
morphological changes previously observed with chloro-
quine, only 9% of parasites recovered from the 6h
chloroquine treatment. Conceivably, this is due to the ir-
reversible accumulation of chloroquine in the parasite
food vacuole due to pH trapping [13], which effectively
counteracts removal of the drug from exposed parasites
by washing. However, it has been reported that chloro-
quine may be effectively washed out of treated parasites
[14]. An alternative explanation could be that free heme
Figure 2 Parasite morphology after 6–8 hours of drug treatment. Plasmodium falciparum 3D7 parasite cultures were incubated for 8 hours
with 100 nM chloroquine or 10 mM DFMO, or for 6 hours with 100 nM mefloquine, 100 nM artemisinin, 100 μM ritonavir or 0.1 nM gramicidin.
Giemsa-stained thin blood smears were prepared from drug-exposed and solvent control cultures and viewed by bright-field light microscopy
using a 100x oil-immersion objective. In each case, three representative images of control (upper row) and treated (lower row) parasites are
shown.
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tion in the 6h incubation [15] remains associated with
parasite membranes and continues to exert toxicity dur-
ing the subsequent 48h after chloroquine removal.
Drug-induced changes in transgenic parasite luciferase
levels
While assessing the effect of anti-malarial compounds
on transgenic parasites expressing luciferase, it was un-
expectedly found that luciferase activity markedly and
rapidly decreased soon after drug exposure. To explore
if this phenomenon extends to the six drug panel used
in the ATP and other assays described above and the
extent to which the luciferase activity changes correlate
with the previous results, cultures containing parasites
stably expressing firefly luciferase were incubated with
the respective compounds for 10 hours and luciferase
activity determined at 2h intervals using the lumines-
cent Bright-GloW luciferase assay reagent (Promega).With chloroquine and DFMO treatment, there was
only a modest and gradual decline in luciferase activity
in treated parasites (Figure 4). By the 10h time-point,
luciferase activity had decreased by 20% and 17% in
chloroquine and DFMO treated parasites, respectively.
By contrast, artemisinin, mefloquine and ritonavir pro-
duced rapid and profound reductions in luciferase ac-
tivity. Luciferase activity had decreased by 67%, 44%
and 34% after only 2h treatments with artemisinin,
mefloquine and ritonavir respectively. Luciferase activ-
ity had been virtually abolished (93% decrease) after 4h
of artemisinin treatment and 6h of ritonavir treatment
(92% decrease; Figure 4). The luciferase activity de-
crease was less severe in the mefloquine treated para-
sites and activity remained at 37% - 31% of the control
levels during the 4–10 hour period. Gramicidin treat-
ment produced an intermediate decrease in luciferase
activity. Activity had decreased by 33% at the 6h time-
point and 43% at 10h.
Figure 3 Parasite recovery from a 6-hour drug exposure.
Plasmodium falciparum 3D7 parasite cultures were incubated for 6
hours with 100 nM chloroquine, 10 mM DFMO, 100 nM mefloquine,
100 nM artemisinin, 100 μM ritonavir or 0.1 nM gramicidin. The
infected erythrocytes were washed and returned to culture in drug-
free medium for an additional 48 hours, after which pLDH activity
was determined for each culture (solid bars). Percentage parasite
viability was calculated from pLDH activity relative to solvent-treated
controls after subtraction of background values obtained with
uninfected control erythrocyte cultures. Each drug treatment was
performed in three parallel cultures and the bars represent the
mean percentage parasite viability values and the error bars
standard deviation.
Figure 4 Variation in luciferase activity in drug-treated
transgenic parasites. Plasmodium falciparum 3D7 parasites
expressing firefly luciferase were incubated for 10 hours with
chloroquine, DFMO , mefloquine, artemisinin , ritonavir or gramicidin
in 96-well plates. At 2-hour intervals, luciferase activity in drug-
exposed and solvent control cultures was determined with a
luminescence based Bright-GloW Luciferase Assay System reagent
(Promega). At each time-point, luminescence is plotted as a
percentage relative to that obtained with controls incubated with
solvent alone, after background luminescence produced by
uninfected red blood cells had been subtracted. Individual data-
points are the mean relative luminescence values from three
replicate wells and error bars indicate standard deviation.
Khan et al. Malaria Journal 2012, 11:369 Page 7 of 11
http://www.malariajournal.com/content/11/1/369To determine if the rapid reduction in luciferase activ-
ity is due to proteasomal digestion as a drug stress re-
sponse, the effect of two proteasome inhibitors,
lactacystin and MG-132 [16], on drug-induced luciferase
activity reduction was assessed. Treatment concentra-
tions with the two inhibitors were based on their re-
spective IC50s (Additional file 2). Parasites were
incubated for 6h in medium containing respectively mef-
loquine, lactacystin or MG-132, or mefloquine in com-
bination with lactacystin or MG-132, and parasite
luciferase levels determined (Figure 5). As expected,
mefloquine treatment for 6h caused a 58% decrease in
luciferase activity. However, both lactacystin and MG-
132 alone also markedly decreased luciferase activity (by
58% and 28% respectively) and this effect was further
exacerbated by co-incubation with mefloquine. This sug-
gests that proteasome degradation is not responsible for
the luciferase activity reduction and, moreover, that the
decrease in luciferase levels also extends to the two pro-
teasomal inhibitors and may be a general parasite re-
sponse to drug exposure.Discussion
In this study, two assay formats as a means for deter-
mining the timing and severity of drug-induced stress in
Plasmodium falciparum parasite cultures over short in-
cubation periods were explored. A panel of six anti-
malarial drug compounds with different modes and, pre-
sumably, rates of action were used to interrogate and
characterize the utility of the ATP and luciferase assays
described above. The observed responses of trophozoite-
stage parasite ATP content to drug exposure over a 10
hour incubation period can be broadly classified into
three phenotypes: little or no change relative to un-
treated controls (chloroquine and DFMO); marked and
sustained increase in ATP levels (mefloquine and arte-
misinin); rapid depletion of ATP content (ritonavir and
gramicidin). These classifications may conceivably be
interpreted as signifying, respectively: absence of signifi-
cant drug-induced stress; altered (increased) metabolic
activity to counteract drug-induced stress; severely com-
promised metabolic status due to drug action. This in-
terpretation correlates with the results obtained with
subsidiary assays. Morphological evaluation of the drug-
treated parasites revealed mild abnormalities, mostly
limited to growth retardation, in the ATP non-respon-
ders, and (with the exception of chloroquine) compe-
tence to recover from a 6h drug exposure. By contrast,
Figure 5 Effect of proteasome inhibitors on mefloquine-
induced luciferase activity decrease. Plasmodium falciparum 3D7
parasites expressing firefly luciferase were incubated for 6 hours with
100 nM mefloquine, 5 μM lactacystin or 300 nM MG-132, or with
100 nM mefloquine combined with lactacystin or MG-132 in a 96-
well plate. Luciferase activity in drug-exposed (solid bars) and
solvent control (shaded bars) cultures was determined with a
luminescence based Bright-GloW Luciferase Assay System reagent
(Promega). Individual data-points are mean luminescence values
(relative light units – RLU) from three replicate wells and error bars
indicate standard deviation.
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of growth-inhibited parasites and additional aberrant
morphologies and a 44%-54% reduction in recovery fol-
lowing 6h drug exposure, while rapid ATP depletion was
accompanied by the early appearance and preponder-
ance of pyknotic (presumably irretrievably compro-
mised) parasite forms and a significantly greater
inhibition (79%-89%) of parasite recovery following 6h
drug exposure. Interestingly, the timing and magnitude
of the ATP changes, whether increased or decreased,
also correlated with the timing of appearance of abnor-
mal morphologies and ability to recover from brief drug
exposure, although arguably more compounds will need
to be assessed to determine the validity of this trend.
Based on these results, the rate and severity of drug
stress can be tentatively ranked as ritonavir>gramicidi-
n>artemisinin>mefloquine>>chloroquine, DFMO.
The lack of a notable ATP response with DFMO
agrees with its accepted mode of action, which is cyto-
static rather than cytocidal. It inhibits ornithine decarb-
oxylase, a key enzyme in polyamine biosynthesis, which
slows down growth and eventually blocks parasite cell
cycle progression in the late trophozoite stage in a man-
ner which is reversible by exogenous addition of polya-
mines to the medium [5]. Thus, a 10h incubation with
DFMO starting in the early trophozoite stage maygenerate insufficient stress to result in a notable disrup-
tion of ATP homeostasis. The consensus view is that
chloroquine becomes ionized and trapped in the low pH
environment of the parasite food vacuole, where it dis-
rupts haemozoin formation and causes an accumulation
of toxic free haem and chloroquine-haem complexes
[17]. The results of this study suggest that a 10h incuba-
tion with chloroquine from the early trophozoite stage
does not generate sufficient haem complexes to exert a
significant effect on parasite ATP levels and/or haem-
induced toxicity is slow-acting. Interestingly, the failure
of parasites to recover from the 6h chloroquine incuba-
tion in the recovery assay may provide additional evi-
dence for the irreversible entrapment of chloroquine in
the food vacuole, where it probably continues to cause
haem accumulation and toxicity despite the washing
away of exogeneous chloroquine in the medium. Thus,
the trapping phenomenon likely contributes greatly to
the effectiveness of chloroquine as an anti-malarial drug,
despite the apparently slow rate at which it induces
metabolic stress compared to the other compounds. An
alternative explanation is that haem accumulating in the
parasite during the 6h chloroquine treatment remains
parasite associated after chloroquine washout and con-
tinues to exert toxicity in the following 48h incubation.
Despite decades of clinical use, the mode of action of
mefloquine is still uncertain. A general assumption is
that it shares chloroquines effect on haemozoin forma-
tion and causes a toxic accumulation of haem or haem
complexes [18]. However, cell biological evidence e.g.
the differential effects of the two drugs on haemoglobin
endocytosis, trafficking and digestion suggests otherwise
[19,20]. In the present study, the rapid and marked effect
of mefloquine on ATP levels and luciferase activity is
not mirrored by chloroquine and thus strongly implies a
different primary mode of action for mefloquine. As for
mefloquine, the mode of action of artemisinin is uncer-
tain and has been suggested to involve inter alia inhib-
ition of the parasite equivalent of the sarcoplasmic
reticulum Ca2+-ATPase (PfATP6), depolarization of
mitochondrial membranes, haem adduct formation, gen-
eration of reactive oxygen species in conjunction with
haem and protein alkylation [21]. Nonetheless, the ap-
peal of artemisinin as an anti-malarial is partly based on
its perceived rapid action against parasites [4], which is
supported by the observations from this study that ATP
and luciferase activity levels in treated parasites are
markedly affected by the drug at the first 2h time-point
of exposure. Uncertainty regarding the modes of action
of mefloquine and artemisinin make it difficult to fully
explain the cause for increased ATP levels in treated
parasites, other than to make a general assumption that
it reflects increased metabolic activity by the parasite
as part of a cellular stress response to overcome
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increased production of ATP to fuel synthesis and activ-
ities of enzymes, substrates and co-factors involved in
e.g. antioxidant defence and protein chaperone systems.
The very rapid and profound depletion of ATP in
ritonavir-treated parasites was supported by the early
preponderance of pyknotic parasite morphologies and
highly compromised ability to recover from a 6h drug
exposure. This was surprising, given that ritonavir is an
HIV protease inhibitor and was proposed to act against
parasites by inhibiting aspartyl proteases responsible for
haemoglobin digestion [22]. Arguably, inhibition of this
process would result in a more protracted growth inhib-
ition of parasites due to amino acid starvation, not the
rapid and lethal effect observed here. This argues for a
different mode of action of ritonavir, which was also pro-
posed in a study reporting the anti-malarial interactions
of HIV protease inhibitors with hemoglobin protease
inhibitors, mefloquine and chloroquine [23]. The rapid
depletion of parasite ATP by gramicidin, however, is
consistent with its probable mode of action. Gramicidins
are lipophilic, linear peptides that form channels in
membranes that are permeable to monovalent cations
[24]. The rapid disruption of cellular sodium, potassium
and proton gradients through these channels should
have immediate pleiotropic consequences for parasite
metabolism, which may also be reflected by the extreme
potency of gramicidin against parasites (IC50 < 0.1nM –
Additional file 2).
The results obtained with the ATP assay suggest that
it could represent a sensitive, quantitative means for
detecting the earliest time-points of drug-induced stress
to inform and complement drug mode of action studies.
However, the question remains whether it could also be
a useful tool for unambiguously determining the rate
and extent to which parasite viability is irrevocably com-
promised by a particular drug. In principle, a total deple-
tion of ATP could have been regarded as a signpost for
irreversible parasite lethality. However, this is not en-
tirely the case, as evidenced by the ability of ritonavir
and gramicidin-treated parasites to recover from a 6h
treatment, albeit severely limited, despite an apparent
complete reduction in ATP in 2–4 hours. Conversely, ar-
temisinin and mefloquine treated parasites actually dis-
play increased ATP levels at 6h, despite the fact that
their recovery from a 6h treatment is inhibited by ap-
proximately 50%. The fact that treatment with the panel
of six drugs produces three distinct phenotypes of ATP
responses (increased, decreased and unchanged ATP
levels) may further complicate a detailed interpretation
of ATP responses to experimental drug pressure, neces-
sitating an exploration of ATP responses with a larger
drug panel before considering scale-up of the assay. In
addition, 5xIC50 drug concentrations were used in thisstudy as a compromise to obtain sufficient drug pressure
on the parasite without excessive off-target effects unre-
lated to the primary drug mode of action which may be
prevalent at higher concentrations. However, it should
be cautioned that 5xIC50 does not necessarily equate to
lethal dose to the same extent for all compounds. There-
fore, rate of killing studies may best be performed at le-
thal dose concentrations. Characterization of the assay,
perhaps in conjunction with the recently described para-
site recovery rate (PRR) assay [4], would be required to
more firmly define the correlates of ATP levels and irre-
versible parasite lethality. Nonetheless, the proposed
ranking of the test drugs based on ATP responses, as
discussed above, suggests that the assay in its current
form may be used to assess the rate of parasite viability
inhibition of experimental compounds relative to each
other and standard “benchmark” drugs.
Serendipitously, it was found that luciferase activity in
transgenic parasites responds rapidly and markedly to
drug exposure. A highly attractive advantage of the luci-
ferase assay is that it is entirely multiwell plate-based,
requires minimal liquid handling steps and provides an
extremely sensitive and robust read-out, thus making it
potentially amenable to high-throughput formats. The
overall trend in the results was similar to that obtained
with the ATP assay. DFMO and chloroquine produced a
slow, mild decrease in luciferase activity, while artemisi-
nin, mefloquine and ritonavir profoundly compromised
luciferase activity within 2 hours. The rapid decreases in
luciferase activity during drug exposure could be con-
strued as a cellular stress response in which proteolysis
and amino acid release and/or selective translational in-
hibition is used to alter the proteome of the parasite
[25,26]. Luciferase is particularly known to be suscep-
tible to proteolytic degradation [27]. Nonetheless, the ac-
tivity decrease was not affected by proteasome
inhibitors, even though proteasomes are principally re-
sponsible for cytoplasmic protein turnover and homeo-
stasis in mammalian cells [26]. Interestingly, the
proteasome inhibitors on their own also produced
marked loss of luciferase activity in 6 hours, suggestive
of parasite stress experienced by the inhibition of their
protein turnover ability. The rapid loss of luciferase ac-
tivity is also not shared by all parasite cytoplasmic pro-
teins. In contrast to luciferase, parasite pLDH activity
showed only mild changes after 6 hours incubation with
all the drugs, which hints that luciferase is particularly
sensitive to cellular stress conditions. Caution should be
exercised in interpreting the luciferase results, however.
The luciferase assay requires the overexpression of a for-
eign reporter protein in the parasite. Conceivably, this
could cause subtle alterations that may obscure drug-
specific effects in subsequent drug mode of action stud-
ies (e.g. by transcriptomic, proteomic or metabolomic
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alter parasite sensitivity and the rate of drug-induced
stress by certain compounds. For example, the detailed
ranking of compound rate of action in the luciferase
assay would differ from that obtained by the ATP assay.
Artemisinin produced more profound and rapid changes
in luciferase activity than the other drugs, while gramici-
din had a milder effect than expected from the earlier
assays (ATP, morphology and parasite recovery). While
mindful of these caveats, the ease of the assay still sug-
gests that it could be used as a preliminary screen for
rapid vs. slow acting compounds over a 4–6 hour incu-
bation period, especially when a large number of com-
pounds need to be assessed.
Conclusion
The magnitude, nature and rate of changes in ATP levels
in parasites incubated with drug compounds appear to
correlate well with the severity and rate of drug-induced
parasite stress, as judged by the recovery of parasites
from a brief drug exposure and morphological changes.
It suggests that the assay may be used to detect the early
time-points of drug action for mode of action studies
and to rank the rate of parasite viability inhibition of ex-
perimental compounds relative to each other and con-
ventional drug standards. Luciferase activity in
transgenic parasites decreased profoundly and rapidly
during drug exposure at rates broadly comparable to
those observed in the ATP assay. While correlation with
parasite recovery and morphological changes were not
as conclusive as that obtained with ATP, it may be useful
as an initial screening tool to differentiate between rapid
and slow acting compounds.
Additional files
Additional file 1: Figure A1. Correlation of ATP luminescence signals
with parasite numbers and stages. A. Aliquots were removed from a
trophozoite-stage culture and the parasites isolated. Serial dilutions of the
parasites were performed in PBS and ATP levels measured. Parasite
numbers were calculated from the percentage parasitaemia and red
blood cell concentration (determined with a haemocytometer) of the
original culture. Three samples were processed in parallel. Note that the
lowest parasite number (1.23x105) corresponds to approximately 4μl of a
2% parasitaemia, 5% haematocrit culture (or 0.2μl packed red blood cells)
and produced an average luminescence reading of 7030. B. Ring-stage
parasites were isolated from three 0.5ml aliquots of a sorbitol
synchronized 5% haematocrit 10% parasitaemia culture and snap-frozen
in liquid nitrogen. After 24h, additional 0.5ml aliquots were removed
from the same culture and used to prepare frozen trophozoite-stage
parasites. After thawing, ATP luminescence signals in the samples were
determined and compared to background signals obtained with aliquots
of uninfected red blood cell cultures processed in parallel. The
trophozoite samples produced a mean luminescence reading of 354054,
compared 13121 for rings and 993 for uninfected red blood cells (note
the log scale of the Y-axis).
Additional file 2: Table 1. IC50 values of compounds used in this
study. IC50 values were obtained by incubating P. falciparum 3D7cultures with serial dilutions of the test compounds for 48 hours and
assessing parasite viability using the parasite lactate dehydrogenase
(pLDH) assay. Values are shown as averages ± standard deviation for
three independent determinations. IC50 values for lactacystin and MG-
132 were determined on a single occasion against luciferase-expressing
parasites.
Additional file 3: Figure A2. ATP changes during trophozoite
development. A tightly synchronized culture of Plasmodium falciparum
3D7 parasites was obtained by enriching trophozoite/schizont-infected
red blood cells by centrifugation through 60% Percoll, incubating the
enriched cells with fresh red blood cells in culture medium for 8 hours,
followed by sorbitol treatment. After a further overnight incubation, the
parasites had reached the trophozoite stage (0 hours image above) and
ATP levels were measured every 2 hours over an 8 hour period.
Representative images of Giemsa-stained thin-smears of parasitized red
blood cells at the various time points of trophozoite development used
in the ATP time-course assay are shown below the graph.
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